|
 |
Myeloproliferative DisordersThis page contains recent news articles, when available, and an overview of Myeloproliferative Disorders but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.News: Myeloproliferative Disorders PR Newswire (press release)CYT387, a novel oral JAK1/JAK2 inhibitor focused on the treatment of myeloproliferative disorders, is also being investigated in a Phase I/II clinical study ... Leerink Swann Initiates Coverage on Incyte Corp (INCY) with an Outperform ... - Nov 2, 2009 StreetInsider.com (subscription)Significant upside should also be driven by INCB18424 in myeloproliferative disorders and INCB28050 in inflammatory disorders. We view INCY shares as fairly ... YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED ... - Nov 17, 2009 PR Newswire (press release)CYT387, a novel oral JAK1/JAK2 inhibitor focused on the treatment of myeloproliferative disorders, is also being investigated in a Phase I/II clinical study ... YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS - Nov 11, 2009 Trading Markets (press release)...a novel, orally-active JAK1/2 inhibitor that recently received clearance from the FDA to commence a Phase I trial in myeloproliferative disorders which ... YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS - Nov 12, 2009 PR Newswire (press release)...a novel, orally-active JAK1/2 inhibitor that recently received clearance from the FDA to commence a Phase I trial in myeloproliferative disorders which ... Incyte Reports Third Quarter 2009 Financial Results and Provides Update on ... - Nov 5, 2009 Reuters2009 reflected the Company`s initial sales and marketing preparations for the potential commercialization of INCB18424 for myeloproliferative disorders. ... Etiology, Management, and Outcome of the Budd-Chiari Syndrome - Aug 3, 2009 Annals of Internal MedicineConclusion: Most patients with BCS have at least 1 thrombotic risk factor, and many have more than 1; myeloproliferative disorders are most common. Cephalon, Inc. Q2 2009 Earnings Call Transcript - Aug 4, 2009 Seeking AlphaOur phase II trial in myeloproliferative disorders with Lestaurtinib should conclude in the next few months. A Phase-I clinical study with CEP-18770 a Incyte Reaches Agreement with FDA on a Special Protocol Assessment - Jul 25, 2009 Trading Markets (press release)Srdan Verstovsek, MD, Ph.D., Associate Professor, Leukemia Department, Myeloproliferative Disorders Program Leader, University of Texas MD Anderson Cancer Incyte Reaches Agreement with FDA on a Special Protocol Assessment ... - Jul 21, 2009 FOXBusinessMyelofibrosis is part of a related group of hematological neoplasms called myeloproliferative disorders that includes myelofibrosis, polycythemia vera and Incyte Reports Second Quarter 2009 Financial Results and Provides ... - Jul 30, 2009 Genetic Engineering News (press release)2009 reflected our initial sales and marketing preparations for the potential commercialization of INCB18424 for myeloproliferative disorders. Inhibition of the Bcl-x L Deamidation Pathway in ... - Dec 24, 2008 New England Journal of Medicine (subscription),The molecular mechanisms in myeloproliferative disorders that prevent apoptosis induced by damaged DNA are obscure. Methods We searched for abnormalities of Pathway Inhibited in Myeloproliferative Disorders Defect seen in ... - Dec 25, 2008 Modern Medicine,25 (HealthDay News) -- In patients with myeloproliferative disorders, inhibition of the Bcl-x L deamidation pathway may increase DNA damage and the risk of Presentation on Cytopia's JAK2 Inhibitor Program in ... - Dec 7, 2008 MarketWatch...by Dr Thomas Bumm of Oregon Health and Sciences University and will overview the study of CYT387 in an in- vivo model of myeloproliferative disorders. Late-Breaking Data Highlighting Research Advances in Several Blood ... - Dec 6, 2008 MarketWatchMyeloproliferative disorders develop when the DNA of a stem cell is altered in the bone marrow, causing the overproduction of some blood cells. Signaling Pathway May Be CML Therapy Target - Dec 26, 2008 MedPage Today,26 -- New therapeutic approaches to two myeloproliferative disorders, chronic myeloid leukemia and polycythemia vera, may emerg,e from a series of cellular Exelixis Reveals New Phase I Data Of XL019 Demonstrating Evidence ... - Dec 7, 2008 RTT News,Myeloproliferative disorders, which result in an overproduction of blood cells, include polycythemia vera, essential thrombocytosis, primary or idiopathic Novel Pathway Involved In Therapy-resistant Cancers Discovered - Dec 24, 2008 Science Daily (press release)Addenbrooke’s Hospital, using cells from patients with chronic myeloid leukaemia (CML), and polycythemia vera (PV), two myeloproliferative disorders. Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates ... - Dec 6, 2008 WELT ONLINE,Srdan Verstovsek, MD, Ph.D., Associate Professor, Leukemia Department, Myeloproliferative Disorders Program Leader, University of Texas MD Anderson Cancer Research and Markets: A Competitor Analysis for Janus Kinase (JAK ... - Dec 10, 2008 MarketWatchJAK2 gain-of-function mutations (JAK2V617F) underlie a subset of disorders collectively referred to as myeloproliferative disorders. The most advanced JAK2 S*BIO Enters Research Collaboration with Tan Tock Seng Hospital ... - Dec 18, 2008 MarketWatchThe V617F mutation is found in high frequencies in various myeloproliferative disorders such as idiopathic myelofibrosis. SB1518 might also provide an Cytopia drug shows potential in treating bone marrow cancers - Dec 10, 2008 SmartBrief,...experimental medicine called CYT387 inhibited JAK2-V617F, an enzyme mutation responsible for bone marrow cancers known as myeloproliferative disorders. Exelixis Reports Phase 1 Data for XL019 at ASH Annual Meeting - Dec 7, 2008 WELT ONLINE,..."With these newest data, XL019 continues to show evidence of clinical activity in patients with myeloproliferative disorders at tolerable doses,�? said Stem cells - the promise and the reality - Dec 6, 2008 Malaysia Star,...and chronic leukaemia, myeloproliferative disorders, bone marrow failure (aplastic anaemia), some genetic metabolic disorders and haemoglobinopathies. Experimental Drug Fights Bone Marrow Cancers - Dec 9, 2008 Washington Post,9 (HealthDay News) -- An experimental drug called CYT387 blocks an enzyme that causes bone marrow cancers called myeloproliferative disorders (MPDs), Seattle Genetics Announces Interim Safety Analysis Supports ... - Dec 10, 2008 MarketWatch...which is expressed on a number of hematologic malignancies, including AML, myelodysplastic syndromes (MDS) and several myeloproliferative disorders. Promising New Drug Blocks Mutation In Bone Marrow Cancers - Dec 9, 2008 Science Daily (press release)In both cases, it blocked the growth of certain bone marrow cancers called myeloproliferative disorders, also referred to as MPDs. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial ... - Dec 2, 2008 PharmaLive.com (press release),The V617F mutation is found in high frequencies in myeloproliferative disorders such as CIMF. It is estimated that approximately 50% of patients with CIMF Cytopia drug shows potential in treating bone marrow cancers - Dec 10, 2008 SmartBrief,...experimental medicine called CYT387 inhibited JAK2-V617F, an enzyme mutation responsible for bone marrow cancers known as myeloproliferative disorders. 陈笃生医院与S*Bio 测试治疗罕�?血癌�?� - Dec 19, 2008 �?��?�早报,S*Bio昨天�?�表文告宣布，公�?�昨天与陈笃生医院签议，测试代�?�SB1518的物质对骨髓增生性疾病（myeloproliferative disorders 新加�?�‧醫院與生物科技公�?��?�手測試‧新抗癌藥5年內推出 - Dec 20, 2008 星洲日報,S*Bio週四（12月18日）發表文告宣佈，公�?�週四與陳篤生醫院簽議，測試代號SB1518的物質�?骨髓增生性疾病（myeloproliferative disorders BloodCenter of Wisconsin Names Roger D. Klein, MD, JD, Medical ... - 18 Nov 2008 MarketWatch...new tests aimed at a variety of cancer diagnostics, including hematological cancers such as leukemia, lymphoma, and myeloproliferative disorders. Atlas of Clinical Hematology - 18 Nov 2008 Journal of American Medical Association (subscription),...tackles myeloid disorders and presents illustrated data on the acute leukemias, myelodysplastic syndromes, and myeloproliferative disorders. Cytopia Doses First Brain Cancer Patient In Phase Ib/II Study - Nov 17, 2008 Medical News Today (press release),...with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in early 2009. Piper Jaffray Downgrades Exelixis (EXEL) to Neutral - Oct 29, 2008 StreetInsider.com (subscription),...from $65 million) due to uninspiring data in gastric cancer, XL184 in MTC at $50 million, and XL019 in myeloproliferative disorders at $67 million. SGX Pharmaceuticals Inc - Premium Company Profile - New Research ... - Nov 14, 2008 Live-PR.com (Pressemitteilung),SGX Pharmaceuticals has two programs in discovery stage, namely, JAK2 inhibitor and RAS inhibitor, for the treatment of myeloproliferative disorders and Les mutations de JAK2 dans les syndromes myéloprolifératifs en 2008 - Nov 12, 2008 Hématologie,27 Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Modélisation de la dynamique de l’hématopoïèse normale et pathologique - Nov 12, 2008 Hématologie,Myeloproliferative Disorders Hydroxyurea and periodicity in myeloproliferative disease. Eur J Haematol 2001 ; 66 : 317-23. 24 Morley A, Baikie A, Cytopia Strengthens Scientific Team With US-Based Drug Development ... - Jul 9, 2008 MarketWatch...with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase 1 clinical studies in early 2009. Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave ... - Jun 17, 2008 Earthtimes (press release),In addition, S*Bio received orphan drug approval from FDA to conduct clinical trials for a drug that is designed to treat myeloproliferative disorders (MPD) 2008-07-02 19:55:17 - www.companiesandmarkets.com adds new report ... - Jul 2, 2008 PR-Inside.com (Pressemitteilung),SGX Pharmaceuticals has two programs in discovery stage, namely, JAK2 inhibitor and RAS inhibitor, for the treatment of myeloproliferative disorders and Dacogen Failure in MDS Phase III Offers Boost to Celgene's Vidaza - Jul 1, 2008 BioWorld Online,...lymphoma and myeloproliferative disorders; SGI-1776, a PIM kinase inhibitor for AML; and S-110, a DNA methyltransferase inhibitor for solid tumors. SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits In Vivo Tumor Cell ... - Jun 17, 2008 Medical News Today (press release),..."We are optimistic that SGI-1252 may be effective in treating leukemia, lymphoma and myeloproliferative disorders and look forward to advancing this SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell ... - Jun 16, 2008 CNNMoney.com (press release)..."We are optimistic that SGI-1252 may be effective in treating leukemia, lymphoma and myeloproliferative disorders and look forward to advancing this Singapore drug-development firm receives 'orphan' approval from US - May 14, 2008 Earthtimes (press release),The drug, code-named SB1518, is meant to treat myeloproliferative disorders. Characterized by a proliferation of certain blood cells, the disorders can lead S*BIO receives orphan drug designation for - May 15, 2008 Checkbiotech.org (press release),...has granted orphan drug designation to SB1518, its potent and orally-active JAK2 inhibitor for the treatment of myeloproliferative disorders (MPD). Health Briefs - 26 Mar 2008 Arbutus Times,Board certified in hematology, medical oncology, and internal medicine, Heyman has special interests in myeloproliferative disorders, acute leukemia, Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative ... - Mar 17, 2008 Earthtimes,Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET) that affect over Upbeat outlook on life - Feb 29, 2008 Journal Times,Myeloproliferative disorders is the general term for a closely related group of progressive blood cancers like the one with which Blocks was diagnosed. Seattle Genetics Initiates SGN-33 Clinical Trial in Combination ... - Mar 20, 2008 Earthtimes,...that targets the CD33 antigen, which is expressed on a number of hematologic malignancies, including AML, MDS and several myeloproliferative disorders. New Genetic Test Detects Rare, Deadly, Difficult-to-Diagnose Blood ... - Mar 7, 2008 PR Web (press release),The JAK2 mutation is also found in approximately half of all patients who are diagnosed with other similar myeloproliferative disorders, such as Essential Incyte To Webcast A Discussion Of Its JAK Inhibitor, INCB18424 ... - Dec 5, 2007 WELT ONLINE,The discussion will feature Srdan Verstovsek, MD, Ph.D., Associate Professor Leukemia Department, Myeloproliferative Disorders and Program Leader, S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic ... - Dec 10, 2007 Earthtimes,..."We are pleased to announce data for the first time on our JAK2 inhibitor, SB1518, and its potential treatment of myeloproliferative disorders, Data Presented At The American Society Of Hematology 49th Meeting ... - Dec 16, 2007 PR-USA.net (press release),Srdan Verstovsek, MD, PhD., Associate Professor Leukemia Department, Myeloproliferative Disorders Program Leader, University of Texas MD Anderson Cancer Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel ... - Dec 10, 2007 CNNMoney.comXL019 is a highly selective inhibitor of JAK2 that may have the potential to provide important benefit for patients with myeloproliferative disorders and Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation ... - Dec 7, 2007 Reuters...analysis provides the hematologist/oncologist with a new diagnostic tool in the identification and management of myeloproliferative disorders, or MPD, Ipsogen launches the first quantitative mutation kit - Dec 14, 2007 Medical Laboratory World,Traditionally, the diagnosis of MyeloProliferative Disorders (MPDs) is based on clinical, bone marrow, histological, immunophenotypic and cytogenetic 49th Annual Meeting of the American Society of Hematology Will ... - Dec 5, 2007 Earthtimes,Lecture on Saturday, December 8, from 12:30 pm to 1:30 pm Dr. Skoda's lecture will focus on the molecular basis of myeloproliferative disorders (MPDs). A Super(Gen) Play on Cancer Biotech Consolidation - Dec 16, 2007 Seeking Alpha,Also in pre-clinical development is a JAK2 kinase inhibitor, which has demonstrated activity in solid tumors and myeloproliferative disorders. IPSOGEN To Undertake Pilot Study On JAK2 Cancer Biomarker With ... - Dec 3, 2007 Medical News Today (press release),...solution of products and services in order to assist pharmaceutical companies in the development of JAK2 inhibitors in myeloproliferative disorders. Background information on Myeloproliferative Disorders [When available] The myeloproliferative diseases are a group of diseases of the bone marrow where excess cells are produced. The delineation from leukemia is artificial, although the myeloproliferative diseases on the whole have a much better prognosis than the leukemias. The concept was first proposed in 1951 by the eminent hematologist William Dameshek. The myeloproliferative diseases are:
Search the web for more resources on Myeloproliferative Disorders |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
